ACTRN12613000133730招募中1 期
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors
Hutchison Medipharma Ltd0 个研究点目标入组 25 人开始时间: 2013年2月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Signed Informed Consent Form ,locally advanced, or metastatic solid malignancy ;Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1;Male or female patients of child-producing potential must agree to take contraception measures to avoidance of pregnancy during the study and for 90 days after the last day of treatment;
- •Patients with gastric cancer , NSCLC, colorectal cancer, breast cancer and hepatocellular carcinoma(HCC) are preferred to be enrolled into the study.
排除标准
- •Inadequate hematologic and organ function, defined by the following ;
- •Clinical significant active infection;
- •Adverse events from prior anti-cancer therapy that have not resolved to Grade = 1, except for alopecia;
- •Pregnant or lactating women;
- •History of myocardial infarction ;
- •Active or untreated brain metastasis;
研究者
相似试验
终止
1 期
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of A-337 in Patients with Advanced Solid TumorsCancerACTRN12617001181392INC Research Pty Ltd4
招募中
1 期
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients with Advanced Solid TumorsAdvanced solid tumoursCancer - BreastCancer - Ovarian and primary peritonealCancer - ProstateACTRN12616000689471IMPACT Therapeutics Australia Pty Ltd30
招募中
不适用
A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.ACTRN12616000008426Suzhou NeuPharma Co., Ltd.35
进行中（未招募）
1 期
Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)EUCTR2017-001684-21-GBeurov Acquisition LLC25
进行中（未招募）
1 期
Phase 1, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of NV1205 in Pediatric Male Subjects with Childhood Cerebral Adrenoleukodystrophy (CCALD)EUCTR2017-001684-21-FReuroVia, Inc.25